TD Asset Management
RYTM icon

TD Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

TD Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.31M Hold
38,778
– – ﹤0.01% 836
2026
Q1 		$3.37M Sell
38,778
-16,272
-30% -$1.58M ﹤0.01% 865
2025
Q4 		$5.89M Sell
55,050
-4,514
-8% -$479K ﹤0.01% 770
2025
Q3 		$6.02M Buy
59,564
+3,564
+6% +$331K ﹤0.01% 756
2025
Q2 		$3.54M Buy
56,000
+5,800
+12% +$355K ﹤0.01% 815
2025
Q1 		$2.66M Buy
50,200
+2,400
+5% +$133K ﹤0.01% 894
2024
Q4 		$2.68M Buy
47,800
+16,000
+50% +$884K ﹤0.01% 927
2024
Q3 		$1.63M Buy
31,800
+800
+3% +$38.3K ﹤0.01% 1094
2024
Q2 		$1.27M Buy
31,000
+3,400
+12% +$136K ﹤0.01% 1118
2024
Q1 		$1.2M Sell
27,600
-10,200
-27% -$446K ﹤0.01% 1142
2023
Q4 		$1.74M Buy
+37,800
New +$1.19M ﹤0.01% 1055
2020
Q1 		– Sell
-21,459
Closed -$493K – 1429
2019
Q4 		$493K Hold
21,459
– – ﹤0.01% 1247
2019
Q3 		$463K Sell
21,459
-1,100
-5% -$23.6K ﹤0.01% 1190
2019
Q2 		$496K Buy
22,559
+3,900
+21% +$98.5K ﹤0.01% 1183
2019
Q1 		$511K Buy
18,659
+3,300
+21% +$94.8K ﹤0.01% 1188
2018
Q4 		$413K Buy
15,359
+797
+5% +$22K ﹤0.01% 1259
2018
Q3 		$425K Buy
14,562
+2,903
+25% +$91.7K ﹤0.01% 1327
2018
Q2 		$364K Buy
+11,659
New +$319K ﹤0.01% 1330

Other funds holding RYTM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TD Asset Management's RYTM Position: Q2 2026 in Review

TD Asset Management held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 38,778 shares worth $4.31M. The position accounts for ﹤0.01% of the portfolio, ranked #836.

TD Asset Management first reported a position in RYTM in Q2 2018 and has held it in 18 quarters since. The position peaked at $6.02M in Q3 2025. 200 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • TD Asset Management held 38,778 shares of Rhythm Pharmaceuticals worth $4.31M as of Q2 2026.
  • TD Asset Management left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #836 holding.
  • TD Asset Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 18 quarters since.
  • TD Asset Management's Rhythm Pharmaceuticals position peaked at $6.02M in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.